No Data
Outlook Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $50
Outlook Therapeutics: Poised to Capitalize on Market Opportunities With LYTENAVA Amidst Industry Shifts
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $50 Price Target
12 Health Care Stocks Moving In Thursday's After-Market Session
Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series